Citations

Clear

6273 citation(s) found for "To, Andrew".

Performance of Creatinine and Cystatin C-Based Equations to Estimate Glomerular Filtration Rate Among Patients With Heart Failure
Roth, John , Lieske, John C. , Arruda‐Olson, Adelaide M. , Herrmann, Joerg , McCallum, Wendy , Larson, Timothy S., Rule, Andrew D. , Rule, Andrew D , Titan, Silvia M , Lieske, John C , Roth, John , Herrmann, Sandra M. , Titan, Silvia

Mayo Clinic

Circulation: Heart Failure | August 15, 2025 | Volume: 18 | Issue: 10 | Pages: No page available

10.1161/circheartfailure.125.013014 | PMID 40814784 Get It

BACKGROUND: The performance of estimated glomerular filtration rate (eGFR) among patients with heart failure (HF) may be worse than in the general population due to a higher prevalence of confounding factors affecting creatinine and cystatin C. Studies in this area are scarce and not stratified by type of HF. We evaluated the performance of current creatinine and cystatin C equations (eGFRcr, eGFRcys, and eGFRcrcys) compared with measured GFR (mGFR) among patients with HF stratified by ejection fraction. METHODS: We pulled data on Mayo Clinic patients with an mGFR performed for clinical indications from 2011 to 2023, with serum creatinine and cystatin C measured within 7 days and an echocardiogram performed up to 1 year before the mGFR date. HF was identified by the presence of International Classification of Diseases codes within 1 year before the mGFR and subgrouped into ejection fraction (EF) ≥50% (HFEF≥50%, n=182) or <50% (HFEF<50%, n=115) and compared with no-HF controls (n=1871). CKD-EPI (and EKFC) eGFRcr, eGFRcys, and eGFRcrcys equations were calculated and compared for bias (mGFR minus eGFR) and accuracy (1-P30, proportion of people with ≥30% difference between eGFR and mGFR). CIs were generated by bootstrapping. RESULTS: The HF groups were characterized by older age, higher proportion of males, more diabetes, higher creatinine, and higher cystatin C than controls. In terms of bias, eGFRcr overestimated mGFR to a greater extent in both HF groups compared with controls, whereas eGFRcys and eGFRcrcys showed similar bias in both HF groups and controls. In the HF groups, cystatin C-based equations were more accurate than eGFRcr, particularly within HFEF<50% (1-P30 of 28% and 34% for CKD-EPI eGFRcys and eGFRcrcys, respectively, versus 60% for eGFRcr), whereas eGFRcrcys was more accurate in controls. The CKD-EPI and EKFC equations were overall convergent, showing similar results. CONCLUSIONS: Among patients with HF, eGFRcr demonstrates inferior performance (more bias and less accuracy) compared with cystatin C-based eGFRs, with this effect being more pronounced in those with HFEF<50%.
Deep Learning-Based Instance-Level Segmentation of Kidney and Liver Cysts in Computed Tomography Images of Patients Affected by Polycystic Kidney Disease
Gregory, Adriana , Khalifa, Muhammed, Im, J G, Ramanathan, Sumana, Elbarougy, Doaa E. , Cruz, Conrad , Yang, Hana , Đenić, Aleksandar , Rule, Andrew D. , Chebib, Fouad T. , Harris, Peter C. , Potretzke, Theodora A. , Kline, Timothy L. , Gregory, Adriana V , Im, Jeeho, Dahl, Neera K , Hogan, Marie C , Harris, Peter C , Torres, Vicente E , Erickson, Bradley J , Potretzke, Theodora , Kline, Timothy L , Rule, Andrew D , Denic, Aleksandar , Chebib, Fouad T , Elbarougy, Doaa E , Khalifa, Muhammed, Im, Jeeho, Dahl, Neera K. , Hogan, Marie C. , Torres, Vicente E. , Erickson, Bradley J.

Mayo Clinic

Kidney360 | August 14, 2025 | Volume: 7 | Issue: 1 | Pages: 117-130

10.34067/kid.0000000924 | PMID 40811034 Get It

Key Points Automated cyst segmentation in autosomal dominant polycystic kidney disease could transform care by enabling precise monitoring of cyst progression with minimal manual effort. This technology can facilitate more consistent assessments of cyst burden across patients. Translating these segmentation models from magnetic resonance imaging to computed tomography is crucial for providing comprehensive, modality-independent evaluations. Background Total kidney and liver volumes are key image-based biomarkers to predict the severity of kidney and liver phenotype in autosomal dominant polycystic kidney disease (ADPKD). However, magnetic resonance (MR) imaging-based advanced biomarkers like total cyst number and cyst parenchyma surface area have been shown to more accurately assess cyst burden and improve the prediction of disease progression. The main aim of this study was to extend the calculation of advanced biomarkers to other imaging modalities; thus, we propose a fully automated model to segment kidney and liver cysts in computed tomography (CT) images. Methods Abdominal CTs of patients with ADPKD were gathered retrospectively between 2001 and 2018. A three-dimensional deep learning method using the nnU-Net architecture was trained to learn cyst edges-cores and the noncystic kidney/liver parenchyma. Separate segmentation models were trained for kidney cysts in contrast-enhanced CTs and liver cysts in noncontrast CTs using an active learning approach. Two experienced research fellows manually generated the reference standard segmentation, which were reviewed by an expert radiologist for accuracy. Results Two-hundred CT scans from 148 patients (mean age, 51.2±14.1 years; 48% male) were used for model training (80%) and testing (20%). In the test set, both models showed good agreement with the reference standard segmentations, similar to the agreement between two independent human readers (model versus reader: TCN kidney/liver r =0.96/0.97 and CPSA kidney r =0.98, inter-reader: TCN kidney/liver r =0.96/0.98 and CPSA kidney r =0.99). Conclusions Our study demonstrates that automated models can segment kidney and liver cysts accurately in CT scans of patients with ADPKD.
Brain signatures of nociplastic pain: Fibromyalgia Index and descending modulation at population level
Kelleher, Eoin , Wanigasekera, Vishvarani , Seymour, Ben , Segerdahl, Andrew R. , Irani, Anushka , Kelleher, Eoin M , Seymour, Ben , Segerdahl, Andrew Reilly , Irani, Anushka , Lange, Frederik , Rathod‐Mistry, Trishna , Nichols, Thomas E. , Tracey, Irene

Mayo Clinic

Brain | August 14, 2025 | Volume: 149 | Issue: 4 | Pages: 1365-1380

10.1093/brain/awaf307 | PMID 40819274 Get It

Abstract Nociplastic pain is defined by altered nociceptive processing in the absence of clear peripheral damage or somatosensory lesions. The Fibromyalgia Index (FMI), derived from the 2016 diagnostic criteria, is increasingly used as a marker of nociplastic pain severity in clinical studies, yet its neurobiological validity remains untested at scale. Using multimodal neuroimaging data from over 40 000 participants in UK Biobank, we examined whether FMI scores were associated with altered functional and structural connectivity within the descending pain modulatory system (DPMS), a brain network involved in endogenous pain control and implicated in nociplastic pain conditions. Functional connectivity was assessed using resting-state functional MRI (rfMRI), and structural connectivity using diffusion-weighted MRI (dMRI) tractography. Connectivity was quantified between seven DPMS regions: periaqueductal grey (PAG), rostral ventromedial medulla (RVM), hypothalamus, amygdala, rostral and subgenual anterior cingulate cortex (rACC, sgACC), and dorsolateral prefrontal cortex (dlPFC). Multi-group structural equation models tested associations between FMI scores and connectivity, stratified by chronic pain status. Mediation models evaluated which aspects of nociplastic pain accounted for the observed associations: widespread pain and SPACE symptoms (sleep disturbance, pain, affect, cognitive problems, and low energy). To assess specificity, we repeated analyses using the Douleur Neuropathique 4 (DN4), a measure of neuropathic pain, and average pain intensity as comparison outcomes. In 22 139 individuals with chronic pain (58% female; mean age 64.8, standard deviation 7.59), FMI scores were associated with altered structural connectivity between the PAG and amygdala [β = 0.023, 95% confidence interval (CI): 0.0087 to 0.039; Pcorr = 0.0125] and between the PAG and hypothalamus (β = −0.029, 95% CI: −0.043 to −0.015; Pcorr = 0.0013). Functional connectivity in the same circuits showed smaller effects. These associations were not observed in individuals without chronic pain. Mediation analyses revealed that PAG-amygdala and PAG-hypothalamus connectivity were partially explained by fatigue, sleep duration, and widespread pain. DPMS connectivity was not significantly associated with neuropathic pain or average pain intensity. These findings suggest that FMI scores reflect biologically meaningful changes in brain connectivity, particularly in subcortical DPMS circuits implicated in affective and homeostatic dimensions of pain. Structural connectivity was more strongly associated with FMI than functional measures, possibly reflecting cumulative effects of chronic pain on white matter architecture. The absence of similar associations for other pain outcomes supports the specificity of FMI as a marker of nociplastic pain severity. These results provide a neurobiological basis for the FMI and support its use in population research and biomarker development for nociplastic pain.
Plasma proteomic analysis identifies proteins and pathways related to Alzheimer's risk
Huang, Yen-Ning , Liu, Shiwei , Park, Tamina, Chaudhuri, Soumilee , Carrasquillo, Minerva M. , Ertekin‐Taner, Nilüfer , Bice, Paula J. , Blennow, Kaj , Russ, Kristen A., Dage, Jeffrey L. , Brosch, Jared R. , Farlow, Martin R. , Clark, David G., Mathew, Sunu , Unverzagt, Frederick W. , Gao, Sujuan , Apostolova, Liana G. , Foroud, Tatiana, Risacher, Shannon L. , Nho, Kwangsik, Kuchenbecker, Lindsey A. , Dage, Jeffrey L , Carrasquillo, Minerva M. , Zetterberg, Henrik , Nudelman, Kelly , Cruchaga, Carlos , Wang, Sophia , Wilcock, Donna M. , Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | August 14, 2025 | Volume: 21 | Issue: 8 | Pages: No page available

10.1002/alz.70579 | PMID 40810263 Get It

Abstract INTRODUCTION We investigated associations of plasma proteins with blood‐based amyloid/tau/neurodegeneration/inflammation (A/T/N/I) biomarkers for Alzheimer's disease (AD). METHODS Plasma proteomics and clinical data from the Indiana AD Research Center ( N = 498) were used. Association analysis of plasma proteins with blood A/T/N/I biomarkers as well as diagnosis was performed, followed by replication in an independent cohort ( N = 323), network analysis, pathway enrichment, and machine learning classification to identify proteins and pathways related to AD risk. RESULTS We identified 35 proteins associated with AD, 20 of which were replicated in the independent cohort. We identified 150, 448, and 219 proteins associated with T/N/I biomarkers, respectively, revealing biomarker‐specific pathways. Network analysis identified two modules associated with T/N/I biomarkers, preserved in cerebrospinal fluid (CSF), and their enriched pathways. The classification model of proteins effectively differentiated AD (area under the curve [AUC] = 0.930). CONCLUSION Our findings suggest dysregulated plasma proteins and pathways in AD, enhancing our understanding of molecular mechanisms and diagnostic strategies for AD. Highlights Plasma proteins were identified as being associated with Alzheimer's disease (AD) and plasma biomarkers. The identified proteins were replicated in both plasma and cerebrospinal fluid (CSF) proteomics. The identified proteins were associated with AD biomarker‐specific pathways. The identified proteins improved the performance of the AD classification. Protein network analysis identified network modules and their enriched pathways.
Quality assurance of the inter‐spot beam delivery of a dose driven continuous scanning proton therapy system
Chua, Clifford Ghee Ann , Lew, Kah Seng, Koh, Calvin Wei Yang , Wibawa, Andrew , Master, Zubin , Lee, James Cheow Lei, Beltran, Chris , Tan, Hong Qi , Beltran, Chris J , Furutani, Keith M. , Lee, Kang Hao , Park, Sung Yong

Mayo Clinic

Medical Physics | August 14, 2025 | Volume: 52 | Issue: 8 | Pages: No page available

10.1002/mp.18050 | PMID 40804772 Get It

Abstract Background Dose‐driven continuous scanning (DDCS) is a type of beam delivery in Hitachi pencil beam scanning (PBS) particle therapy system. Particle beam is irradiated continuously between spots to achieve a higher effective dose rate and a shorter beam delivery time. The beam is only turned off at break spots, the end of a treatment layer and during spill change. The break spot is a unique feature of the DDCS introduced by the treatment planning system (TPS) to interrupt continuous scanning. DDCS separates the dose delivery of a spot into a move dose and stop dose components. The move dose is controlled by the scanning speed and beam current, while the stop dose delivers the remaining monitor units (MUs). Hence, rigorous quality assurance (QA) of the scanning speed and functionality of break spot are required to ensure safe and successful DDCS delivery. Purpose We aim to report for the first time the QA methodology and result for DDCS, focusing on the scanning speed and break spot validation. Methods A rectangular spiral irradiation pattern with different degree of break spots were irradiated on a 2D strip ionization chamber (CROSSmini) detector using 50 time resolution to validate the break spots. Four methods of measuring scanning speeds were proposed. Using a spiral irradiation pattern, methods one and two applied linear regression to the scanning time measured by the CROSSmini for different inter‐spot distances, with measurements taken at sampling rates of 5 and 20 kHz, respectively. Methods three and four measured the scanning time of single inter‐spot distances in the X and Y directions. Method three measured the scanning time with the CROSSmini while method four measured the rise and fall time of the scanning magnet (SCM) current. All measurements were performed with 70.2, 150.2 and 228.7 MeV proton beam energies and three different beam currents of 8, 14 and 20 MU/s. Lastly, the scanning speed tolerance limit was calculated analytically under the requirement of avoiding a beam abort when the stop dose was less than zero. Results The data recorded by the CROSSmini under the spiral irradiation patterns with break spots was reconstructed into a 2D dose, and the break spots’ operations were visually validated for all the energies and beam currents. There were no statistically significant difference in the measured X and Y scanning speeds across the four methods. However, the last method involving the SCM current yielded the largest type A uncertainty of up to 25% () due to the noisy signal. The first method with the linear regression and 5 kHz acquisition rate was preferred due to a smaller type A uncertainty of up to 2.0% and a lower false negative rate in detecting the rising and falling edges during scanning. The calculated tolerance limit based on our current DDCS setting was found to be 0.50 times of the expected scanning speed. Conclusion We have introduced QA protocols for DDCS, designed to ensure complete and safe beam delivery without interruptions caused by move doses exceeding planned spot doses.
Non-invasive biomarkers for monitoring portal hypertension in metabolic dysfunction-associated steatotic liver disease (MASLD)
Pal, Shreya C. , Ramírez‐Mejía, Mariana M. , Keaveny, Andrew P. , Méndez‐Sánchez, Nahúm

Mayo Clinic

Expert Review of Gastroenterology & Hepatology | August 14, 2025 | Volume: 19 | Issue: 9 | Pages: 1021-1032

10.1080/17474124.2025.2548526 | PMID 40803998 Get It

Consensus Statements—Optimizing Performance of the Elite Athlete
Bangsbo, Jens , Hostrup, Morten , Hellsten, Ylva , Hansen, Mette Halskov, Egan, Brendan , Hackney, Anthony C. , Chambers, Toby L. , Deshmukh, Atul S. , Elliott‐Sale, Kirsty J. , Joyner, M. J., Christensen, Peter M. , Kissow, Julie , Jeppesen, Jan S. , Moesgaard, Lukas , Egan, Brendan , Hackney, Anthony C , Magnusson, Peter , Calbet, Jose A L , Elliott-Sale, Kirsty , Joyner, Mike, Christensen, Peter M , Joyner, Michael J , Rømer, Tue , Wickham, Kate A , Jessen, Søren K , Jeppesen, Jan S , Moesgaard, Lukas , Hellsten, Ylva , Hansen, Mette, Melin, Anna , Kjær, Michael , Burr, Jamie F. , Engebretsen, Lars , Jones, Andrew M. , Pitsiladis, Yannis , Petersen, Jesper, Calbet, José A. L. , Andersen, Jesper L.

Mayo Clinic

Scandinavian Journal of Medicine & Science in Sports | August 9, 2025 | Volume: 35 | Issue: 8 | Pages: No page available

10.1111/sms.70112 | PMID 40781883 Get It

ABSTRACT The International Consensus Conference “Optimising Performance of the Elite Athlete,” held in November 2024, brought together 29 scientists, some coaches, and athletes to establish evidence‐based consensus statements aimed at enhancing elite athletic performance and health. The conference addressed critical themes including training strategies, nutrition, female athlete considerations, injury management, and emerging technologies. Key conclusions emphasize individualized, sport‐specific approaches to training and nutrition, integrating concurrent training modalities to improve endurance, resilience, and efficiency. Nutrition strategies highlight the importance of tailored energy and macronutrient periodization, recognition of low energy availability risks, and cautious use of dietary supplements. Special attention was directed to female athletes, advocating for improved monitoring of menstrual cycles and hormonal status, while acknowledging current knowledge gaps in hormonal influences on performance and injury risk. Injury prevention remains a challenge, with tendon overuse and Achilles tendon ruptures significantly impacting athlete careers; rehabilitation should rely on criteria‐based progression and multidisciplinary input. Emerging technologies, including wearable sensors and multi‐omics analyses, hold promise for personalized training and nutrition but require further validation in elite contexts. Despite robust consensus, the panel identified substantial research gaps, particularly regarding female athletes, longitudinal training effects, and efficacy of novel interventions. This consensus provides a practical, scientifically grounded framework to optimize elite athlete performance and health, while underscoring the need for continued research to address outstanding questions and promote inclusive evidence‐based practices.
Cytokine, Chemokine, and Neurofilament Light Chain Signatures in LGI1 Autoimmune Encephalitis
Aboseif, Albert , Mangioris, Georgios , Yang, Binxia , Dubey, Divyanshu , Irani, Sarosh R. , Day, Gregory S. , Howe, Charles L. , López‐Chiriboga, A. Sebastian , Mills, John R. , Tolédano, Michel B. , Vodopivec, Ivana, Ζεκερίδου, Αναστασία , Dubey, Divyanshu , Dubey, Divyanshu , Irani, Sarosh R , Day, Gregory S , Howe, Charles L , McKeon, Andrew , Segal, Yahel, Pittock, S J , Zekeridou, Anastasia , Dubey, Divyanshu , Aboseif, Albert , Yang, Binxia , Pazdernik, Vanessa , Britton, Jeffrey W. , Flanagan, Eoin P. , McKeon, Andrew , Segal‬‏, Yahel , Toledano, Michel, Pittock, Sean J.

Mayo Clinic

Annals of Clinical and Translational Neurology | August 9, 2025 | Volume: 12 | Issue: 11 | Pages: 2258-2270

10.1002/acn3.70158 | PMID 40781580 Get It

ABSTRACT Objectives To investigate the value of cytokine, chemokine, and neurofilament light chain (NfL) concentrations in predicting relapse risk, chronic epilepsy, and functional impairment in LGI1 autoimmune encephalitis (AE). Methods Cytokines/chemokines (IL‐1‐beta, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8/CXCL8, IL‐10, IL‐12p70, IL‐13, IL‐17A, GM‐CSF, TNF‐alpha, IFN‐gamma, CXCL9, CXCL10, CXCL13, BAFF) and NfL concentrations were measured in CSF and paired serum from LGI1‐AE patients evaluated at Mayo Clinic (01/2015–02/2024), using a multiplex immunoassay system (ELLA, Bio‐Techne) and correlated with clinical outcomes. A laboratory‐based cohort of LGI1‐IgG‐positive patients and control cohorts, including patients with mixed non‐inflammatory disorders (MNID), Alzheimer's disease (AD), and temporal lobe epilepsy (TLE) were analyzed. Results Forty‐four patients with LGI1‐AE were included; 29 (66%) were male, with a median age of 68.5 years (range, 8–85). Median time from symptom onset to CSF sampling was eight months (IQR, 3–17); 19/42 (45%) experienced a clinical relapse and 27% developed chronic epilepsy. Serum IL‐6, serum and CSF IL‐8/CXCL8, and IL‐17A were higher in LGI1‐IgG positive patients than MNID ( p < 0.05). TLE cytokine/chemokine profiles were similar to LGI1 AE; AD patients had lower serum IL‐6 and CSF IL‐8/CXCL8 ( p = 0.04; p = 0.01), and higher serum IL‐17A and GM‐CSF ( p = 0.004; p = 0.01) than LGI1‐AE. Higher CSF IL‐6 and IL‐8/CXCL8 in LGI1‐AE associated with clinical relapse ( p < 0.05) and higher CSF NfL associated with chronic epilepsy ( p = 0.01). Conclusion Elevations in IL‐6, IL‐8/CXCL8, and IL‐17A were identified in this LGI1‐AE cohort. CSF IL‐6, IL‐8/CXCL8, and NfL levels are potential prognostic biomarkers for risk of relapse and chronic epilepsy in LGI1‐AE.
Platelets regulate glioblastoma growth and immunity via sex-dependent PAR4 - Estrogen receptor beta signaling
Sloan, Anthony , Bukenya, George, Tannish, Gavin P., Silver, Daniel J., Aggarwal, Anu, Lee, Juyeun, Rosoff, Daniel, Alban, Tyler J., Juric, Ivan, Parsai, Shikha, Baruah, Vargab, Tack, Liza, Navadgi, Tanvi, Reitz, Natalie, Ho, Shawn T., Badani, Aarav, Goldberg, Jessica, Yuan, Xueer, Gaboriau, Aymerick, Kamatala, Samrutha, Coker, Jesse, Kumar, Vrishabhadev Sathish, Jain, Saachi S., Scalise, Alliefair, Rajasekar, Bhairavi, Vincenti, Alex, Mulkearns-Hubert, Erin E., Horbinski, Craig M., Sloan, Andrew E., Hubert, Christopher G., Lohoff, Falk W. , Goodman, Wendy A., Miller, Tyler E., O’Connor, Christine M. , Lathia, Justin D. , Sloan, Anthony R , Luo, Jingqin , Rubin, Joshua B , Stavrou, Evi X , O'Connor, Christine M , Cameron, Scott J , Tannish, Gavin P., Silver, Daniel J., Aggarwal, Anu, Lee, Juyeun, Rosoff, Daniel, Alban, Tyler J., Juric, Ivan, Parsai, Shikha, Baruah, Vargab, Tack, Liza, Navadgi, Tanvi, Reitz, Natalie, Ho, Shawn T., Badani, Aarav, Goldberg, Jessica, Yuan, Xueer, Gaboriau, Aymerick, Kamatala, Samrutha, Coker, Jesse, Kumar, Vrishabhadev Sathish, Jain, Saachi S., Scalise, Alliefair , Rajasekar, Bhairavi, Vincenti, Alex, Mulkearns-Hubert, Erin E., Horbinski, Craig M., Sloan, Andrew E., Hubert, Christopher G., Stavrou, Evi X. , Goodman, Wendy A., Miller, Tyler E., Nieman, Marvin T. , Sangwan, Naseer , Chan, Timothy An-thy , Khorana, Alok A. , Dhawan, Andrew , Cameron, Scott J.

Mayo Clinic

No container title available | August 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.08.06.668464 | PMID 41959130 Get It

Abstract Sex differences in cancer outcome, including that of glioblastoma (GBM), are shaped by biological, hormonal, and immunological factors and impact disease progression, treatment responses, survival, and tumor microenvironment (TME) interactions. Platelets regulate the immune responses and tumor progression in many cancers, but it is not clear how they contribute to these sex-based differences by affecting the dynamics of the TME. Here, we show that GBM patients exhibit heightened platelet reactivity driven by PAR4 signaling. In murine GBM models, both pharmacological inhibition of PAR4 using BMS986120 and genetic deletion of PAR4 significantly prolong survival in females but not males. This survival advantage is estrogen dependent: it is preserved in chromosomal male-hormonal female mice within the four-core genotype model and is rescued in ovariectomized mice treated with estrogen. The survival benefit is TME specific and is mediated by platelet-driven enhancement of CD8⁺ T cell infiltration into the tumor. Inhibition of platelet PAR4 signaling increases calcium signaling through an estrogen-dependent interaction between PAR4 and estrogen receptor β (ERβ)—a receptor interaction not previously described. PAR4-activated platelets within the TME suppress CD8⁺ T cell function, and depletion of CD8⁺ T cells abolishes both the tumor-induced platelet reactivity and the survival benefit conferred by PAR4 inhibition. These findings establish platelet-mediated PAR4 signaling as a critical driver of tumor progression and identify sex-specific immune responses as key to therapeutic efficacy.
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in Pulmonary Hypertension in Interstitial Lung Disease: A PVRI GoDeep Meta-Registry Analysis
Yogeswaran, Athiththan , Fünderich, Meike , Balasubramanian, Aparna , Konswa, Ziad , Kiely, David G. , Thenappan, Thenappan , Eichstaedt, Christina A. , Olschewski, Horst , Sweatt, Andrew J. , Zamanian, Roham T. , Giannakoulas, George , Elwing, Jean , Beckmann, Stephan, Olsson, Karen M. , Held, Matthias , Halank, Michael , Milger, Katrin , Pausch, Christine , Pittrow, David , Majeed, Raphael W. , Wilhelm, Jochen , Tello, Khodr , Seeger, Werner , Ghouleh, Imad Al , Sіrenko, Yu.M. , Balasubramanian, Aparna , Lawrie, Allan , Wilkins, Martin , Howard, Luke , Olschewski, Horst , Frantz, Robert, Stadler, Stefan , Hoeper, Marius M , Thenappan, Thenappan , Seeger, Werner , Yogeswaran, Athiththan , Kiely, David , Majeed, Raphael W , Hassoun, Paul M. , Saleh, Khaled, Grünig, Ekkehard , Wilkins, Martin R. , Kovács, Gábor , Cajigas, Héctor , Frantz, Robert P. , Sabbour, Hani Mohamed , Arvanitaki, Alexandra , Jose, Arun , Ewert, Ralf , Behr, Jürgen , Ghofrani, Hossein Ardeschir , Grimminger, Friedrich , Hoeper, Marius M.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 7, 2025 | Volume: 211 | Issue: 10 | Pages: 1855-1866

10.1164/rccm.202412-2371oc | PMID 40772955 Get It

Abstract Rationale Pulmonary hypertension (PH) in interstitial lung disease (ILD) lacks approved therapies. Objectives The Pulmonary Vascular Research Institute GoDeep metaregistry collects real-world data of patients with PH from international PH referral centers. Methods Patients with ILD-PH and relevant subgroups (idiopathic interstitial pneumonia [IIP], idiopathic pulmonary fibrosis [IPF]) were stratified by pulmonary vascular resistance (PVR). Kaplan-Meier survival analyses and adjusted Cox proportional hazards models were employed, additionally accounting for immortal time bias, sensitivity analyses, Heller explained relative risk statistics, and target trial emulation framework analysis. Measurements and Main Results Among 34,482 patients, 940 with hemodynamically fully characterized incident ILD-PH (median age, 67 [IQR, 59–74] yr) were identified. A total of 62% had severe ILD-PH with PVR &gt;5 Wood units (WU) and poor survival rates (29% and 18% at 3 and 5 yr), significantly worse than patients with ILD-PH with PVR ≤5 WU and patients with pulmonary arterial hypertension. Survival was poorest in severe IPF-PH. A total of 59% of all patients ILD-PH received PH-targeted therapy, predominantly phosphodiesterase-5 inhibitors (PDE5is). PDE5i treatment was consistently associated with significantly improved survival in patients with severe PH (hazard ratios of 0.537 [0.370–0.781], 0.461 [0.233–0.913], and 0.435 [0.215–0.8] for IIP-PH, IPF-PH, and IIP-PH with nintedanib/pirfenidone background therapy), but not in patients with less severe hemodynamic impairment, supported by sensitivity analyses, Heller statistics, and target trial emulation framework analysis. The survival statistics of patients with PDE5i-treated IIP-PH or IPF-PH were validated in the independent COMPERA registry. Combination therapy with PDE5is and inhaled prostacyclin analogues was superior to monotherapy using PDE5is (hazard ratio, 0.341; 0.205–0.566). Conclusions Prognosis in ILD-PH was generally very poor and was related to PH severity. PDE5i treatment in severe IIP-PH and IPF-PH was associated with improved survival, which is to be further verified in controlled trials.